Last year, Sanofi crossed off Sjögren’s from the list of targeted indications for its CD40L monoclonal antibody frexalimab after seeing phase 2 efficacy data. Novartis removed one other drug ...

Summary: Entrepreneurs often grapple with the decision of whether to structure their business as a Company or a Limited Liability Partnership (LLP). Both offer the advantage of limited liability and ...

•The retinal nerve fiber layer (RNFL) has no myelin and can thereby be considered to be a highly enriched axonal tissue •Changes in the RNFL and macula probably reflect mechanisms of ...

The pathophysiology of multiple sclerosis (MS) is characterized by demyelination, which culminates in a reduction in axonal transmission. Axonal and neuronal degeneration seem to be concomitant ...

Frexalimab is under clinical development by Sanofi and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) ...

Frexalimab is under clinical development by Sanofi and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase II drugs for Relapsing Remitting Multiple ...